The Beneficial Effect of Anticoagulation in Aortic Bioprosthesis is Associated with its Size

Abstract Objective: To evaluate the clinical and echocardiographic outcomes in aortic valve replacement (AVR) patients with aortic bioprosthesis under oral anticoagulation (OA). Methods: Patients who underwent AVR with bioprosthesiswere prospectively enrolled. They were classified based on postoperative use of OA. Clinical and operative variables were collected. Echocardiographic and clinical follow-ups were performed two years after surgery. The primary outcome evaluated was change in transprosthetic gradient. Secondary outcomes analyzed were change in New York Heart Association (NYHA) class, major bleeding episodes, hospitalization, stroke, and transient ischemic attack. Results: We included 103 patients (61 without OA and 42 with OA). Clinical characteristics were similar among groups, except for younger age (76±6.3 vs. 72.4±8.1 years, P=0.016) and higher prevalence of atrial fibrillation (0% vs. 23.8%, P

【摘要】目的：本研究旨在评估接受主动脉生物瓣膜植入的主动脉瓣置换术（aortic valve replacement, AVR）患者在口服抗凝治疗（oral anticoagulation, OA）下的临床与超声心动图结局。
方法：本研究前瞻性纳入接受主动脉生物瓣膜置换术的患者，根据术后是否使用口服抗凝治疗进行分组。收集患者的临床与手术相关变量资料，并于术后2年开展超声心动图及临床随访。本研究的主要结局指标为跨瓣压差变化；次要结局指标包括纽约心脏协会（New York Heart Association, NYHA）心功能分级变化、大出血事件、住院情况、脑卒中及短暂性脑缺血发作。
结果：本研究共纳入103例患者，其中未接受口服抗凝治疗者61例、接受口服抗凝治疗者42例。两组患者临床特征基本相似，仅在年龄（76±6.3 vs 72.4±8.1岁，P=0.016）与心房颤动患病率（0% vs 23.8%，P）方面存在差异。